A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Ulcerative Colitis

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Ulcerative Colitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms MANTA
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 12 Feb 2018 Planned End Date changed from 1 Sep 2022 to 1 Oct 2024.
    • 12 Feb 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Jan 2021.
    • 15 Aug 2017 Planned number of patients changed from 200 to 250.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top